Loading fund overlap…
14 of 37 unique stocks in common · Jaccard: 37.8%
A weighted portfolio overlap of 56.99% indicates a moderate overlap (a meaningful shared core). This means that out of every ₹100 you invest across these two schemes, approximately ₹56.99 is allocated to the exact same companies at the same relative proportions. The schemes share 14 common holdings.
The largest overlapping asset in their portfolios is Sun Pharmaceutical Industries, which commands a weight of 24.92% in Nippon India Nifty Pharma ETF and 13.81% in Nippon India Pharma Fund. Holding both schemes increases your concentration in Sun Pharmaceutical Industries rather than expanding your diversification.
If the overlap is above 30%, it is typically because both schemes benchmark to the same index (e.g. Nifty 50 or Nifty LargeMidcap 250) or overlap in their top large-cap picks. To improve your portfolio's diversification, consider allocating one of these tranches to a category with lower structural correlation (such as a mid-cap, small-cap, or international equity fund).
| Stock | in Nippon India Nifty | in Nippon India Pharma |
|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | 24.92% | 13.81% |
| LupinPharmaceuticals & Biotechnology | 6.11% | 8.55% |
| CiplaPharmaceuticals & Biotechnology | 11.29% | 6.08% |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | 7.84% | 5.05% |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | 11.61% | 4.78% |
| Zydus LifesciencesPharmaceuticals & Biotechnology | 3.71% | 3.61% |
| Aurobindo PharmaPharmaceuticals & Biotechnology | 4.98% | 2.91% |
| Mankind PharmaPharmaceuticals & Biotechnology | 2.62% | 2.99% |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | 3.73% | 2.56% |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | 3.71% | 2.24% |
| Abbott IndiaPharmaceuticals & Biotechnology | 2.16% | 3.20% |
| JB Chemicals & PharmaceuticalsPharmaceuticals & Biotechnology | 2.09% | 3.70% |
| Gland PharmaPharmaceuticals & Biotechnology | 1.82% | 4.08% |
| Sanofi IndiaPharmaceuticals & Biotechnology | 1.15% | 2.75% |
Weighted overlap = Σ min(weight in fund A, weight in fund B) across shared stocks, from each fund's latest public monthly portfolio (as on Apr 2024). Equity holdings only, ISIN-verified. Not investment advice.